What should I do if I become drug-resistant to Ruxolitinib?

Studies show that symptoms of myeloproliferative neoplasms may return to pre-treatment levels in about a week after patients stop taking Ruxolitinib. Some patients with myelofibrosis (MF) experience one or more adverse events after discontinuation, including pyrexia, respiratory distress, hypotension, disseminated intravascular coagulation (DIC), or multiorgan failure.

If one or more of the above conditions occur after discontinuation of the drug or when the dose of ruxolitinib is tapered, evaluate and treat any concurrent disease and consider restarting or adding ruxolitinib. When treatment is stopped or interrupted for reasons other than thrombocytopenia or neutropenia, consideration should be given to gradually reducing the dose of ruxolitinib tablets rather than stopping suddenly. Patients should not interrupt or stop treatment without consulting a doctor. Everyone has a different constitution and has different drug resistance reactions. Please inform your doctor in time if you feel unwell.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.